CSL Seqirus has welcomed the announcement that neffy adrenaline nasal spray will be listed on the Pharmaceutical Benefits Scheme on 1 July, making the product reimbursed for emergency treatment of anaphylaxis in adults and some children.
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
If this is an example of a bully playing hardball, it's not the companies
July 21, 2026 - - Latest News -
LTR Pharma secures national US manufacturing and fulfilment partner
July 21, 2026 - - Latest News -
Candidate shows antidepressant signal in difficult to treat depression
July 21, 2026 - - Latest News -
'Our access. Our medicines. Our vaccines. Our medical technology'
July 21, 2026 - - Latest News -
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News

